CTIS2023-504959-27-00进行中（未招募）1 期
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) - MK-7339-013
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 853
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Has pathologically (histologically or cytologically) confirmed Small Cell Lung Cancer (SCLC). Note: Participants with histology showing a mixed tumor with small cell and non-small cell elements are not eligible, Has adequate organ function, Male and female participants who are not pregnant and of childbearing potential must follow contraceptive guidance during the treatment period and for the time needed to eliminate each study intervention, Male and female participants who are at least 18 years of age at the time of signing the information consent, Male participants must refrain from donating sperm during the treatment period and for the time needed to eliminate each study intervention, Abstains from breastfeeding during the study intervention period and for at least the following period after the last study intervention: - Pembrolizumab: 120 days - Olaparib: 7 days, Has Limited-Stage SCLC (Stage I-III, by AJCC 8th Edition Cancer Staging), and can be safely treated with definitive radiation doses., Has no evidence of metastatic disease by whole body positron emission tomography /computed tomography (PET/CT scan), CT or magnetic resonance imaging (MRI) scans, Has at least 1 lesion that meets the criteria for being measurable, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), Has not received prior treatment (chemotherapy or radiotherapy or surgery resection) of LS-SCLC, Is not expected to require tumor resection during the course of the study, Must submit a pre-treatment tumor tissue sample (formalin-fixed, paraffin embedded blocks are preferred to slides) including cytologic sample, if tissue sample unavailable, Has Eastern Cooperative Oncology Group (ECOG) Performance score 0 or 1 assessed within 7 days prior to the first administration of study intervention, Has a life expectancy of at least 6 months
排除标准
- •Has history, current diagnosis, or features suggestive of myelodysplastic syndrome/ acute myeloid leukemia (MDS/AML), Has a history of (non-infectious) pneumonitis/interstitial lung disease that requires steroids, Has an active infection requiring systemic therapy, Has a known history of human immunodeficiency virus (HIV) infection or Hepatitis B or known active Hepatitis C virus infection, Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PDL1), or anti- programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor, Has received prior therapy with olaparib or with any other polyadenosine 5'diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor, Had major surgery <4 weeks prior to the first dose of study intervention (except for placement of vascular access), Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention, Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention, Has a known additional malignancy that is progressing or has required active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded, Has severe hypersensitivity (= Grade 3) to study intervention and/or any of its excipients, Has an active autoimmune disease that has required systemic treatment in past 2 years
研究者
相似试验
进行中（未招募）
不适用
A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled AsthmaAsthma:Subjects with chronic inflammatory disorder of the airways characterized by recurrent episodes of wheezing, breathlessness, chest tightness, and coughing resulting from abnormal airflow obstruction and constrictionMedDRA version: 13.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-019543-19-HUAmgen Limited300
进行中（未招募）
1 期
A study evaluating the effect of filgotinib on sperm parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis.Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial SpondyloarthritisMedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0 Level: PT Classification code 10002556 Term: Ankylosing spondylitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0 Level: LLT Classification code 10076297 Term: Non-radiographic axial spondyloarthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2018-003933-14-LVGalapagos NV250
进行中（未招募）
1 期
This clinical study evaluates and compares the efficacy and safety of Regorafenib versus placebo in patients with colorectal cancer after curative resection of liver metastasis and completion of all planned chemotherapy.Metastatic Colorectal CancerMedDRA version: 19.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864EUCTR2012-004369-42-GBBayer AG25
进行中（未招募）
1 期
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphomaewly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaMedDRA version: 16.0Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSSystem Organ Class: 100000004864EUCTR2013-000959-40-ESJanssen-Cilag International NV800
进行中（未招募）
1 期
Placebo-controlled Trial of Pembrolizumab in Esophageal Carcinoma Participants Receiving Concurrent dCRTMedDRA version: 21.0Level: LLTClassification code 10015366Term: Esophageal carcinomaSystem Organ Class: 100000004864Esophageal CarcinomaEUCTR2019-002006-51-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc600